LTRN
NASDAQLantern Pharma Inc.
Price$0.65-0.01 (-1.34%)
03:00 PM04:00 PM
News · 26 weeks44+100%
2026-04-192026-10-11
Mix2290d
- Other9(41%)
- SEC Filings9(41%)
- Offering3(14%)
- Earnings1(5%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lantern Pharma Inc.SCHEDULE 13G/A - Lantern Pharma Inc. (0001763950) (Subject)
- SECSEC Form PRE 14A filed by Lantern Pharma Inc.PRE 14A - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that Lantern management will be presenting at the ThinkEquity Conference on Thursday, October 15, 2026, at 3:30 p.m. ET at the Mandarin Oriental in New York, NY.Webcast Link: https://event.summitcast.com/view/GXv6JAoMEphytK6ggozCk7/VS4pGMrvkgq2xwHrNQevWXConference Registration Link: https://www.meetmax.com/sched/event_138793/conference_register.htmlLantern Pharma management will be available for one-on-one meetings held throughout the
- PRLantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLCThe Taiwan FDA approved the amended protocol and the lead Taiwan site received IRB approval during September of 2026. The next stage (Part 2) is a single-arm study enrolling never-smoker patients with the EGFR exon 21 L858R mutation, with LP-300 dosing extended from six to a maximum of eight cycles. EGFR mutations are found in 55% of advanced lung adenocarcinomas in Taiwan and roughly half across Asia, compared with approximately 14% of NSCLC in Europe and 24% in the U.S.; the L858R mutation is also more common in Asian patients. In the U.S., a central IRB has approved the amended protocol and academic sites have begun identifying patients with the L858R mutation for enrollment.
- SECSEC Form 8-K filed by Lantern Pharma Inc.8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECLantern Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern", the "Company" or "we"), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced the closing of its previously announced registered direct offering of 3,669,725 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.09 per share (or pre-funded warrant in lieu thereof). In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 3,669,7
- SECSEC Form 424B5 filed by Lantern Pharma Inc.424B5 - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Inc. Announces up to $8 Million Registered Direct Offering$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern", the "Company" or "we"), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 3,669,725 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.09 per share (or pre-funded warrant in lieu thereof) in a registered direct offering. In addition, in a concurrent private placement, the Company
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- PROpen-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ETManagement will also discuss usage patterns, key future milestones, and an overview of the types of collaborations and partnerships under discussionInvestors, collaborators, prospective partners, and interested parties are encouraged to register and see a live demonstration of the platform's key capabilities: Register HereLantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, will present the growth plan for Open-Medicine AI (OMAI) in a live webinar today at 12:30 PM Eastern. Open Medicine AI is the company's wholly owned subsidiary building a multi-agentic AI platform for drug d
- PRLantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell LymphomasNewly allowed claims provide LP‑284 patent protection into 2042 for the treatment of mantle cell lymphoma and double-hit lymphoma, two blood cancers with high-unmet-needs The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, "Method for Treating Blood Cancers," with claims directed to the use of LP‑284 (hydroxyureamethyl acylfulvene) to treat mantle cell lymphoma (MCL) and double‑hit lymphoma (DHL) Allowed claims include methods of treatment as a monotherapy and in combination with a second anti‑cancer agent — including DNA damage agents, glucocorticoids, immunomodulatory drugs (IMiDs), BCL2 inhibitors, BTK inhibitors
- SECLantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form 10-Q filed by Lantern Pharma Inc.10-Q - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateOpen Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for Biomarker-Selected Bladder Cancer Trial; LP-184 Development Positioned to Advance in Multiple Indications including Triple Negative Breast Cancer and Pediatric Brain Cancers Open Medicine AI (OMAI) established as a separate company with board-approved commercial licensing agreements executed, operating the multi-agentic AI co-scientist platform previously launched as withZeta.ai. OMAI is currently wholly owned by Lantern and intends to raise capital at the OMAI level. A dedicated
- PRLantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ETWebcast to be held Friday, August 14th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® and Open-Medicine AI platforms with multiple clinical stage drug programs, today announced that it will host its second quarter 2026 operating and financial results webcast on Friday, August 14, at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the second quarter ended June 30, 2026 and provide guidance on upcoming milestones, clinical trials
- SECSEC Form SCHEDULE 13G filed by Lantern Pharma Inc.SCHEDULE 13G - Lantern Pharma Inc. (0001763950) (Subject)
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of MedicineThe Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai and is expanding into additional disease areas and modalities. The creation of the new entity, signed commercial licenses, and Board approvals are consistent with the agreements entered into in connection with Lantern’s May financing. Lantern Pharma has executed commercial licensing agreements with Open-Medicine AI granting access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets and personnel. The global AI drug discovery and development market is projected to exceed $10 billion by 2030, and Open-Medicine AI enters this market with a differentiated
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lantern Pharma Inc.SCHEDULE 13G/A - Lantern Pharma Inc. (0001763950) (Subject)
- PRLantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor CancersAllowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven) In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026 Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today anno
- PRLantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every CancerFirst previewed in the company’s May roadmap, the new withZeta.ai module now enters early access with leading bioinformatics teams and Lantern collaborators — autonomously designing experiments, building rigorous cohorts from 615,000+ curated cancer samples, and delivering publication-ready multi-omic analysis in minutes A new class of research agent. ZetaOmics™ is an autonomous "Computational Biologist" that goes beyond automating software — it reasons about experimental design, prevents pitfalls that produce false discoveries, and makes statistically rigorous decisions on its own, encoding the judgment of a tenured bioinformatician so that scientific rigor is the default across rare an
- SECSEC Form EFFECT filed by Lantern Pharma Inc.EFFECT - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form S-1 filed by Lantern Pharma Inc.S-1 - Lantern Pharma Inc. (0001763950) (Filer)
LTRN FAQ
7 questionsWhat does Lantern Pharma Inc. do?
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain...Where does LTRN stock trade?
Lantern Pharma Inc. (LTRN) is listed on NASDAQ.What sector and industry is LTRN in?
Lantern Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Lantern Pharma Inc. go public?
Lantern Pharma Inc. (LTRN) completed its IPO in 2020.What are analysts saying about LTRN?
Lantern Pharma Inc. has had 3 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $3600.00 price target on 2022-03-11. Recent price targets range from $3200.00 to $3600.00.What companies are similar to LTRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LTRN side-by-side with any of them on Quantisnow.How can I track LTRN on Quantisnow?
Quantisnow aggregates Lantern Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LTRN to receive live email and push alerts on every new disclosure.